Literature DB >> 16051859

Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.

Christian Kittel1, Boris Ferko, Martina Kurz, Regina Voglauer, Sabine Sereinig, Julia Romanova, Gabriela Stiegler, Hermann Katinger, Andrej Egorov.   

Abstract

Engineering of the influenza A virus NS1 protein became an attractive approach to the development of influenza vaccine vectors since it can tolerate large inserts of foreign proteins. However, influenza virus vectors expressing long foreign sequences from the NS1 open reading frame (ORF) are usually replication deficient in animals due to the abrogation of their NS1 protein function. In this study, we describe a bicistronic expression strategy based on the insertion of an overlapping UAAUG stop-start codon cassette into the NS gene, allowing the reinitiation of translation of a foreign sequence. Although the expression level of green fluorescent protein (GFP) from the newly created reading frame was significantly lower than that obtained previously from an influenza virus vector expressing GFP from the NS1 ORF, the bicistronic vector appeared to be replication competent in mice and showed outstanding genetic stability. All viral isolates derived from mouse lungs at 10 days postinfection were still capable of expressing GFP in infected cells. Utilizing this bicistronic approach, we constructed another recombinant influenza virus, allowing the secretion of biologically active human interleukin-2 (IL-2). Although this virus also replicated to high titers in mouse lungs, it did not display any mortality rate in infected animals, in contrast to control viruses. Moreover, the IL-2-expressing virus showed an enhanced CD8+ response to viral antigens in mice after a single intranasal immunization. These results indicate that influenza viruses could be engineered for the expression of biologically active molecules such as cytokines for immune modulation purposes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051859      PMCID: PMC1182655          DOI: 10.1128/JVI.79.16.10672-10677.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains.

Authors:  I Babai; Y Barenholz; Z Zakay-Rones; E Greenbaum; S Samira; I Hayon; M Rochman; E Kedar
Journal:  Vaccine       Date:  2001-11-12       Impact factor: 3.641

2.  Intranasal inoculation of a recombinant influenza virus containing exogenous nucleotides in the NS segment induces mucosal immune response against the exogenous gene product in mice.

Authors:  Naomi Takasuka; Masayoshi Enami; Shigeyuki Itamura; Toshitada Takemori
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

3.  Review of intranasal influenza vaccine.

Authors:  R Glueck
Journal:  Adv Drug Deliv Rev       Date:  2001-09-23       Impact factor: 15.470

4.  A genetically engineered influenza A virus with ras-dependent oncolytic properties.

Authors:  M Bergmann; I Romirer; M Sachet; R Fleischhacker; A García-Sastre; P Palese; K Wolff; H Pehamberger; R Jakesz; T Muster
Journal:  Cancer Res       Date:  2001-11-15       Impact factor: 12.701

5.  Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60.

Authors:  Hong Jin; Bin Lu; Helen Zhou; Chienhui Ma; Jackie Zhao; Chin-fen Yang; George Kemble; Harry Greenberg
Journal:  Virology       Date:  2003-02-01       Impact factor: 3.616

Review 6.  Antibody-cytokine fusion proteins: innovative weapons in the war against cancer.

Authors:  J S Dela Cruz; T H Huang; M L Penichet; S L Morrison
Journal:  Clin Exp Med       Date:  2004-10       Impact factor: 3.984

7.  Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice.

Authors:  H Ghiasi; Y Osorio; G C Perng; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

8.  Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes.

Authors:  Tokiko Watanabe; Shinji Watanabe; Takeshi Noda; Yutaka Fujii; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Generation of recombinant influenza virus using baculovirus delivery vector.

Authors:  Kanokwan Poomputsa; Christian Kittel; Andrej Egorov; Wolfgang Ernst; Reingard Grabherr
Journal:  J Virol Methods       Date:  2003-06-09       Impact factor: 2.014

10.  Expression of a foreign gene by stable recombinant influenza viruses harboring a dicistronic genomic segment with an internal promoter.

Authors:  Alexandre Vieira Machado; Nadia Naffakh; Sylvie van der Werf; Nicolas Escriou
Journal:  Virology       Date:  2003-08-15       Impact factor: 3.616

View more
  17 in total

1.  Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency.

Authors:  Markus Wolschek; Elisabeth Samm; Helena Seper; Sanda Sturlan; Irina Kuznetsova; Cornelia Schwager; Alexandra Khassidov; Christian Kittel; Thomas Muster; Andrej Egorov; Michael Bergmann
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

2.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

3.  Recombinant influenza virus carrying the conserved domain of respiratory syncytial virus (RSV) G protein confers protection against RSV without inflammatory disease.

Authors:  Yu-Na Lee; Hye Suk Hwang; Min-Chul Kim; Young-Tae Lee; Min-Kyoung Cho; Young-Man Kwon; Jong Seok Lee; Richard K Plemper; Sang-Moo Kang
Journal:  Virology       Date:  2014-12-30       Impact factor: 3.616

4.  Evaluation of the influenza A replicon for transient expression of recombinant proteins in mammalian cells.

Authors:  Florian Krammer; Jens Pontiller; Christopher Tauer; Dieter Palmberger; Andreas Maccani; Martina Baumann; Reingard Grabherr
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.752

5.  Region required for protein expression from the stop-start pentanucleotide in the M gene of influenza B virus.

Authors:  Masato Hatta; Candice K Kohlmeier; Yasuko Hatta; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry.

Authors:  L Wang; D L Suarez; M Pantin-Jackwood; M Mibayashi; A García-Sastre; Y M Saif; C-W Lee
Journal:  Vaccine       Date:  2008-05-22       Impact factor: 3.641

7.  A novel method to incorporate bioactive cytokines as adjuvants on the surface of virus particles.

Authors:  Yufang Yang; David Leggat; Andrew Herbert; Paul C Roberts; Roys S Sundick
Journal:  J Interferon Cytokine Res       Date:  2009-01       Impact factor: 2.607

8.  Green fluorescent protein (GFP) color reporter gene visualizes parvovirus B19 non-structural segment 1 (NS1) transfected endothelial modification.

Authors:  Thomas Wurster; Catharina Pölzelbauer; Tanja Schönberger; Angela Paul; Peter Seizer; Konstantinos Stellos; Andreas Schuster; Rene M Botnar; Meinrad Gawaz; Boris Bigalke
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

9.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

Review 10.  Engineering influenza viral vectors.

Authors:  Junwei Li; Maria T Arévalo; Mingtao Zeng
Journal:  Bioengineered       Date:  2012-08-24       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.